MDWD250117P18000
- 0.15
- 0.000.00%
MediWound Newsroom
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Mediwound (MDWD)
Buy Rating for Mediwound Driven by EscharEx's Market Potential and Disruptive Role in Chronic Wound Care
Citi Initiates MediWound(MDWD.US) With Buy Rating, Announces Target Price $25
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Mediwound (MDWD) Receives a Buy From TD Cowen
Mediwound Advances in Enzymatic Therapeutics With Strategic Expansions
We're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn Rate
MediWound Approves 2024 Share Incentive Plan to Boost Employee Engagement
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company's Future
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30
Strategic Growth and Market Potential Drive Buy Rating for MediWound Despite Revenue Decline
Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday
MediWound Analyst Ratings
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $25
Express News | Mediwound Ltd. : H.c. Wainwright Cuts Target Price to $25 From $28
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript
MediWound Advances With FDA Approval and New Funding
MediWound Ltd. Advances Development With EscharEx IND Submission Planned for Year-End and NexoBrid FDA Pediatric Approval